Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A study of 599 patients who had died of malignant lymphoma between 1952 and 1972 revealed involvement of the bladder in 13 per cent. Bladder involvement was always a secondary event, occurred in association with disseminated disease and was more common in non-Hodgkin's lymphoma than in Hodgkin's disease. Direct infiltration from adjacent pelvic foci as well as discrete apparent metastatic foci was noted. Involvement was usually microscopic although the presence of gross disease was invariably clinically manifest. Cystoscopy and cystography were valuable in the diagnosis of gross lesions. In contrast to primary vesical lymphoma the treatment of secondary vesical lymphoma was symptomatic and an operation was indicated rarely. Local radiotherapy was effective in treating the symptoms of secondary vesical lymphoma.
 ...
PMID:Secondary involvement of the bladder in malignant lymphoma. 33 Aug 84

The treatment of patients with non-Hodgkin's lymphomas remains controversial. The Rappaport classification system has established its clinical value in distinguishing relatively favorable disease (ie, nodular or follicular lymphoma) from relatively unfavorable disease (ie, diffuse lymphoma). Despite the problems of multiple histologies in a given patient posed by the existence of composite lymphomas and by a spectrum of nodularity in a given node, no newer classification has yet proved superior to the Rappaport system. The relative roles of radiotherapy and chemotherapy are reviewed. The primary role of radiation appears to be the control of detectable disease, when adequate doses and volumes are employed. The primary role of chemotherapy appears to be the eradication of microfoci of tumor. Randomized studies of combined modality approaches have produced no definitive evidence of benefit from adjuvant chemotherapy in stage I and II disease of unfavorable histology. The addition of adjuvant radiotherapy in stage III and IV disease of unfavorable histologic types appears to produce some improvement. Aggressive treatment regimes have yet to show any significant advantage over more conservative treatment in patients with favorable histologic types of stage IV extent. This paper emphasizes the need for expert hematopathologic interpretation in every study of non-Hodgkin's lymphoma.
 ...
PMID:Combined modality therapy in malignant lymphomas. 33 54

The architectural arrangement of the neoplastic cells and their cytologic identification form the histologic basis of the Rappaport classification of non-Hodgkin's lymphomas clinical studies have shown the favorable prognosis of the nodular lymphomas while the diffuse lymphomas irrespective of cell type have a poor prognosis. Several recent studies have shown that pathologists can identify the nodular and diffuse patterns with a high degree of reproducibility. The cytologic subclassification has, however, not achieved a similar high degree of reproducibility. The Southwest Oncology Group study has shown the most reproducible subgroups to be the nodular poorly differentiated lymphocytic malignant lymphoma (ML) and the diffuse histiocytic ML. The clinical significance of the Rappaport classification when applied to childhood lymphomas is not as clear as in adult lymphomas. In view of the recent description of a new clinicopathologic entity primarily in children and adolescents (ie, lymphoblastic ML), IT IS APPARENT THAT THE CHILDHOOD LYMPHOMAS Will have to be examined more critically in order to determine the clinical significance of this classification. Although some have proposed new classifications of these lymphomas based upon immunologic identification of cell origin, none have been shown to be of clinical significance. Based on recent immunologic and clinical studies, a modified classification of the non-Hodgkin's lymphoma is proposed which does not alter its clinical usefulness.
 ...
PMID:Rappaport classification of non-Hodgkin's lymphoma: histologic features and clinical significance. 33 57

Neoplastic tissues from 75 adults with non-Hodgkin's malignant lymphoma, histologically classified according to the Rappaport schema, were studied for B- and T-lymphocyte surface markers. All nodular poorly differentiated lymphocytic lymphomas and diffuse well-differentiated lymphocytic lymphomas were B cell. Of 30 diffuse poorly differentiated lymphocytic lymphomas 16 were B, five were T, and nine were "null"; of ten diffuse histiocytic lymphomas, seven were B and three were null. In patients with diffuse lymphoma, those whose malignant cells demonstrated B markers survived significantly longer than those whose malignant cells demonstrated no markers. The prognostic capabilities of the Rappaport histologic classification and surface marker studies were compared. For patients with diffuse lymphomas, classification as B or null more accurately predicted survival than did identification as lymphocytic or histiocytic. However, survival was best predicted by a classification combining the Rappaport histologic scheme with surface marker studies.
 ...
PMID:Prognostic significance of lymphocytic surface markers and histology in adult non-Hodgkin's lymphoma. 33 59

Lymphoma Pathology Panel and Repository (LPPR) review of pathologic material from 354 patients registered on Southwest Oncology Group clinical trials substantiated the diagnosis of Hodgkin's disease (Lukes-Butler classification) in 175 (94%) of 186 cases and the diagnosis of non-Hodgkin's lymphoma (Rappaport classification) in 162 (96%) of 168 cases. However, complete agreement (type and subtype) between institutional and LPPR review diagnoses was found in only 66% of confirmed cases of Hodgkin's disease and in only 58% of confirmed cases of non-Hodgkin's lymphomas. In 26 (16%) of 160 cases of non-Hodgkin's lymphoma, the initial interpretation of pattern (nodular vs diffuse) differed: 20 (25%) of 81 nodular lymphomas had been thought to be diffuse and 6 (8%) of 79 diffuse lymphomas had been diagnosed as nodular. The frequency with which initial diagnoses were confirmed on LPPR review was highest for three subtypes of lymphoma: nodular sclerosis Hodgkin's disease (88%), diffuse histiocytic lymphoma (86%), and nodular lymphocytic lymphoma (78%); rates of confirmation for all other subtypes ranged from 13-50%. The results of this analysis emphasize the necessity of having pathologic review of all cases entered on major lymphoma studies so that comparability of cases can be assured and the results of those studies placed in proper perspective.
 ...
PMID:Histopathologic review of lymphoma cases from the Southwest Oncology Group. 33 62

A 56-year-old man with chronic lymphocytic leukemia who developed Richter's syndrome is described. The criteria for diagnosis are given and the histology is discussed. We agree that Richter's syndrome represents a peculiar complication of chronic lymphocytic leukemia and not a separate disease entity. As such, Richter's syndrome must be known and recognized by those evaluating patients with lymphadenopathy whose basic diagnosis may be confused with Hodgkin's disease or "histiocytic" lymphoma.
 ...
PMID:Richter's syndrome. 33 29

Alkaline phosphatase (ALP) activity was evaluated histochemically and cytochemically in concert with immunologic technics in 60 cases of non-Hodgkin's lymphomas and lymphocytic leukemias. Surface membranes of neoplastic cells were positive for ALP only in certain B-cell malignancies: 3 of 6 lymphocytic lymphomas of intermediate differentiation, 4 of 13 nodular lymphomas, and 1 of 7 Burkett's lymphomas. All other B-cell tumors, including chronic lymphocytic leukemia, well-differentiated lymphocytic lymphoma, and diffuse "histiocytic" lymphoma, were ALP-negative. The neoplastic cells of Sezary syndrome and lymphoblastic lymphoma were also consistently negative for ALP. In control lymph nodes ALP-positive lymphocytes were present only in primary follicles and in mantle zones of secondary follicles. ALP-positive lymphomas appear to be neoplastic counterparts of these normal lymphocytes, not only cytochemically, but also with respect to their morphologic and immunologic characteristics. Furthermore, histochemical inhibition tests suggested that the ALP activity demonstrated may reflect a newly recognized, unique isoenzyme.
 ...
PMID:Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas. 33 71

Sera from 50 patients with Hodgkin's disease, 78 patients with non-Hodgkin non-leukemic malignant lymphomas, and 75 patients with different types of solid malignant tumors were investigated for the presence of immune complexes using the (125I) C1q-binding test. All patients were untreated. An increased serum C1q-binding activity was found in 22% of the patients with Hodgkin's disease, 35.9% of the non-Hodgkin lymphoma patients and in 37.3% of the patients with solid tumors. The C1q-binding material detected in the patients' sera had properties similar to those of immune complexes. On sucrose density gradient it sedimented as a 10-30 s material. It contained IgG which were dissociated under acid conditions. Passage through anti-IgG immunoabsorbent removed its C1q-binding properties. A prevalent association was found between the presence of serum immune complexes and disseminated disease stages in all the patient groups included. A similar association was found between the presence of serum immune complexes and general symptoms among the malignant lymphoma patients. The nature of the antigens involved in the complexes remains unknown.
 ...
PMID:Circulating immune complexes in patients with malignant lymphomas and solid tumors. 33 14

Piperazinedione given iv once every 3-4 weeks at a starting dose of 9-12 mg/m2 (4.5-12 mg/m2 for patients with myeloma) was evaluated in a Southwest Oncology Group phase II study for patients with far-advanced refractory lymphoma or multiple myeloma. Among 36 patients fully evaluable for tumor response (adequate trial), partial responses were observed in five (71%) of seven patients with Hodgkin's disease, in three (19%) of 16 patients with non-Hodgkin's lymphoma, and in none of 13 patients with multiple myeloma. Response was observed by the time of the second (five patients) or third (three patients) course. The median duration of response was 3.7 months (range, 1-17+ months). The dose-limiting toxic effects were hematologic, with 18 (50%) of 36 patients evaluable for toxicity experiencing severe leukopenia (wbc count less than 2000/mm3) and 22 (61%) experiencing severe thrombocytopenia (platelet count less than 50,000/mm3). Twenty patients had a decrease from their pretreatment hemoglobin level of greater than or equal to 2 g/100 ml. Hematologic toxic effects were often unpredictable and in several patients quite prolonged. This study indicates that piperazinedione had definite antitumor activity in patients with Hodgkin's disease and further trials in this disease using the drug at a reduced dose in combination with other effective drugs appear warranted.
 ...
PMID:Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study. 34 32

Human B lymphocyte antigens (HBLA) were detected with fluorescent-labeled antibodies on malignant cells of 102 patients with Hodgkin disease and other lymphomas, plasma cell myeloma, and nonlymphoreticular neoplasms including carcinomas of the breast, lung, and ovary, soft tissue sarcomas, and neuroblastoma. HBLA were present in Hodgkin disease and other lymphomas of B cell or histiocyte derivation. They were absent in plasma cell myeloma and nonlymphoreticular neoplasms. Absorption studies revealed that malignant T cells had smaller amounts of HBLA, usually not detected by immunofluorescence. Expression of HBLA was dependent on both cell differentiation and origin. Detection of HBLA enabled immunologic distinction of Reed-Sternberg and other lymphoma cells from morphologically similar cells of nonlymphoreticular origin. The rapidity, reproducibility, and economy of the immunofluorescence test make this a useful clinical tool for the differential diagnosis of lymphoma from other malignant disorders in man.
 ...
PMID:B lymphocyte antigens in the differential diagnosis of human neoplasia. 34 89


<< Previous 1 2 3 4 5 6 7 8 9 10